60 results about "Type antigen" patented technology

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The invention relates to a multi-metal element nano-aluminum adjuvant and a preparation method and application thereof, the nano-aluminum adjuvant is a nano-particle containing an aluminum element and at least one metal element selected from magnesium, zinc and calcium, the nano-particle has a layered crystal structure, and the particle size is distributed in a range of 20-2000 nm. The difunctional nano-aluminum adjuvant has the beneficial effects that the difunctional nano-aluminum adjuvant is simple and convenient in preparation method, definite in component and uniform in particle size, the particle size of the particles can be manually regulated and controlled, and the difunctional nano-aluminum adjuvant can directly promote antigen presenting cells to be mature and activated and carry out MHC-I or II type antigen presentation.

The application provides a PLA2R monoclonal antibody and an ELISA kit comprising the antibody. Specifically, the application provides a monoclonal antibody which specifically binds to PLA2R, wherein the antibody only binds to non-reduced PLA2R antigen with a conformational epitope, does not bind to reduced PLA2R antigen, and does not bind to another antigen THSD7A of primary membranous nephropathy. An ELISA kit prepared based on the antibody can more efficiently and accurately detect primary membranous nephropathy than existing commercial kits.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The application provides an anti-Norovirus GII genotype VP1 antigen monoclonal antibody and an application thereof. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain CDR3 shown in SEQ ID NO. 3, and the light chain variable region comprises a light chain CDR3 shown in SEQ ID NO. 6. The monoclonal antibody is a rabbit-derived monoclonal antibody, the monoclonal antibody has good specificity and high affinity, and solves the problem of a mouse-derived monoclonal antibody in actual application. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody has important application value in the preparation of a product for detecting Norovirus.

The invention discloses an FUT2 high-expression cell strain as well as application and a method of the FUT2 high-expression cell strain in vaccine quality control, and belongs to the technical field of vaccines. The technical problem to be solved is that a simple and easy-to-operate cell model is lacked in the prior art, and the cell model is used for evaluating the effectiveness of NoV vaccines on the cellular level. According to the key points of the technical scheme, the FUT2 high-expression cell strain is provided, the cell strain is an HEK 293T cell strain (HEK 293T-FUT2-EGFP) with EGFP fluorescence for overexpressing human alpha 1, 2-fucosyltransferase 2 (FUT2), and the cell strain stably expresses H, Lewis b and Lewis y type HBGA antigens; meanwhile, an alternative neutralization experiment of the cell level of the norovirus vaccine based on the cell strain is developed, a basis is provided for interaction research of the norovirus and host cells, and the cell strain has high practical application value.

The invention discloses a GAGE7 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the GAGE7 recombinant antigen is shown as SEQ ID NO.1. Through verification, compared with a wild type GAGE7 antigen, the detection sensitivity of the GAGE7 recombinant antigen is remarkably improved, and meanwhile, the performance of the GAGE7 recombinant antigen is obviously superior to that of a commercially available GAGE7 recombinant antigen. Therefore, the GAGE7 recombinant antigen has a good application prospect in the field of early detection of lung cancer.

The invention relates to the technical field of computational biology, artificial intelligence and drug discovery, in particular to a Foke-Planck equation-based antibody complementary determining region generation method and device.The method comprises the steps of defining a forward stochastic differential process, constructing a neural network-based generation model, and then obtaining an antibody complementary determining region based on de-noising prediction; an implicit fractional field of the generative model is parsed and a Foke-Planck equation (FPE) residual is calculated to train at least one parameter of the generative model for generating the CDR by minimizing a composite loss function containing regularization terms associated with the FPE residual. Therefore, the problems that a correlation generation model objective function only pays attention to local gradients, neglects global physical coherence and excessively depends on a public database with limited data volume and biased distribution, so that chemical unreasonable or energy unstable conformations are generated, and a novel effective combination mode is difficult to generate due to performance reduction when facing novel antigens are solved; the clinical application value is limited.

The invention discloses a preparation method and application of a Taq DNA polymerase monoclonal antibody based on structural domain analysis, which are specifically different from a traditional method using full-length Taq polymerase as an immunogen (the method generally cannot generate a functional blocking antibody due to a hidden epitope which is difficult to approach). According to the invention, by adopting a structure-oriented and domain-specific strategy, the exposure of epitopes related to active sites is remarkably enhanced, and a novel antigen Taq-P protein is developed. Based on the antigen, a high-specificity inhibitory monoclonal antibody is prepared, and the antibody is expected to become a core component of a high-performance hot start PCR reagent. According to the invention, a novel and generalizable mode is established for the development of a core diagnostic reagent, a key raw material is provided for gene detection and molecular diagnosis, and a valuable methodological framework is contributed to the development of propulsor engineering and biotechnology reagents.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

The invention provides a hybridoma cell strain secreting an IgG1 type monoclonal antibody resisting human N-type blood group antigen, the hybridoma cell strain is named as N1C8 and preserved in the China Center for Type Culture Collection on August 7, 2025, and the preservation number is CCTCC NO: C2025231. The invention further provides a monoclonal antibody secreted by the hybridoma cell strain secreting the IgG1 type monoclonal antibody resisting the human N-type blood group antigen and application of the monoclonal antibody. The cell strain is used for preparing a monoclonal antibody for resisting the human N-type blood group antigen, salt and protein are added into the antibody to develop a human N-type blood group antigen detection reagent, and the human N-type blood group antigen detection reagent can be applied to detection of the human N-type blood group antigen, so that a human N-type blood group antigen detection method is more scientific and perfect.

The invention relates to a duck infectious serositis pentavalent inactivated vaccine as well as a preparation method and application thereof. The vaccine is prepared from a duck infectious serositis type 1 antigen, a duck infectious serositis type 2 antigen, a duck infectious serositis type 6 antigen, a duck infectious serositis type 7 antigen and a duck infectious serositis type 10 antigen. The preparation method comprises the following steps: S1, strain screening; step S2, strain culture; step S3, carrying out inactivation treatment; step S4, bacterial liquid mixing; and S5, emulsifying the adjuvant. The duck infectious serositis pentavalent inactivated vaccine has the advantages of prominent broad spectrum, excellent immune effect and high industrial feasibility, can cover more than 90% of epidemic strains, solves the problem of incomplete prevention of the existing vaccine, has protection rates of more than or equal to 90% on the attack of five serotype virulent poison, adopts a fermentation tank for amplification culture in a culture process, has stable bacterial liquid proliferation efficiency, and is suitable for large-scale production. Emulsifying process parameters are clear and suitable for large-scale production.

The present invention provides novel CD3 antigen binding fragments with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, remaining tumor cell killing and reduced toxicity. The present invention also provides bispecific antigen binding molecules for activating T cells. In addition, the invention further provides methods of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising the above said bispecific antigen binding molecules.

The present application relates to the technical field of tumor immunotherapy. The present application provides a responsive antigen capture nano platform, a preparation method and application thereof. The product of the present application is applied by systemic administration such as intravenous injection; can specifically respond to peroxynitrite in the tumor microenvironment, realize the precise activation of the tumor site; can covalently capture tumor-related antigens through high efficiency, deliver the antigens to antigen presenting cells, so as to enhance the anti-tumor immune response; combined with photodynamic therapy can significantly inhibit tumor growth.

The present invention relates to fibroblast activation protein (FAP)-specific antigen binding molecules, associated fusion proteins and conjugates, and methods of use thereof. In some aspects, the binding molecules comprise a moiety having the form of a shark variable novel antigen receptor (VNAR).

The present disclosure discloses a specific saccharide fragment for development of Vibrio cholerae vaccines, and belongs to the field of medicine. In the present disclosure, a saccharide fragment related to a trisaccharide of V. cholerae O100 serotype O-antigen is chemically synthesized. Combined with a glycan microarray technology, the structure-activity relationship between different saccharide fragments and antigenicity thereof is evaluated at a molecular level. Glycan microarray screening indicates that 3-hydroxybutyryl is an essential structural feature of the O-antigen. A non-reducing end disaccharide carrying 3-hydroxybutyryl is a potential minimal antigenic epitope, and the disaccharide has strong binding capacity to antibodies and a simple structure, and may serves as a specific saccharide fragment for vaccine development. A glycoconjugate vaccine designed based on the specific saccharide fragment may solve the challenges of difficulty in culturing pathogenic bacteria and heterogeneity of saccharide antigens in naturally extracted polysaccharide vaccines. The present disclosure has bright application prospects in the development of glycoconjugate V. cholerae vaccine, infection detection, and new drug development.

This document discloses antibodies targeting CD40 and their uses. It also discloses novel antigen-binding proteins capable of specifically binding to CD40 and their antigen-binding fragments. Furthermore, this document discloses fusion proteins comprising a first domain activating antigen-presenting cells (APCs) (e.g., dendritic cells) and a second domain activating immune effector cells (e.g., T cells), wherein the first domain comprises the antigen-binding protein or its antigen-binding fragment that specifically binds to CD40 disclosed herein.

The invention relates to a blood group antigen detection test strip. The blood group antigen detection test strip comprises a core body, the core body comprises a porous hydrophilic film and a water absorption layer, the porous hydrophilic film is provided with a circular sample introduction area, the diameter of the sample introduction area is 5-10mm, an anti-A monoclonal antibody, an anti-B monoclonal antibody and an anti-D monoclonal antibody are combined in the sample introduction area through sample application treatment, and the diameter of the anti-A monoclonal antibody, the diameter of the anti-B monoclonal antibody and the diameter of the anti-D monoclonal antibody are 5-10mm. The water absorption layer is compounded on the upper surface of the porous hydrophilic film. Solid-phase monoclonal antibodies aiming at different blood group antigens are coated in the sample introduction area in a spotting manner, when vein whole blood or fingertip blood samples are dropwise added into the sample introduction area, the solid-phase monoclonal antibodies can be combined with corresponding antigens in blood to form red indication points, and detection results are quickly displayed. And the rest red blood cells which are not agglutinated can penetrate through the porous hydrophilic film.

The present invention provides novel antigens of an allergy to fish, methods and kits for diagnosing an allergy to fish, a pharmaceutical composition comprising the antigen, fish or fish eggs in which the antigen is eliminated, a processed product of the fish or the fish eggs or fish which lay the fish eggs or have hatched from the eggs, and a tester for determining the presence or absence of a fish antigen in an object of interest.

The invention is applicable to the technical field of genetic engineering, and provides an E2-1b + mi3 protein nanoparticle of bovine viral diarrhea virus as well as a preparation method and application of the E2-1b + mi3 protein nanoparticle, the E2-1b + mi3 protein nanoparticle is formed by coupling an E2-1b-st fusion protein and a mi3-sc fusion protein, the 1b type E2 antigen of the bovine viral diarrhea virus is displayed on the surface of the mi3 protein nanoparticle through an isopeptide bond; the amino acid sequence of the mi3 protein nanoparticle is shown as SEQ ID NO: 6 in a sequence table; the amino acid sequence of the E2-1b-st fusion protein is as shown in SEQ ID NO: 2 in a sequence table; the amino acid sequence of the mi3-sc fusion protein is shown as SEQ ID NO: 4 in a sequence table. After animals are immunized by the E2-1b + mi3 protein nano-particles, an effective immune protection effect can be generated, and the E2-1b + mi3 protein nano-particles have a good prevention and control application prospect on bovine viral diarrhea caused by BVDV 1b type viruses.

The invention belongs to the technical field of biological medicines, and relates to a high-affinity antigen of an autoimmune disease antibody as well as a synthesis method and application of the high-affinity antigen. According to the method, a one-pot multi-enzyme system is utilized, a compound 1 is taken as a starting receptor, and N-acetylglucosamine is connected to a non-reducing terminal of the compound 1 through a beta1, 3-glucosidic bond to generate a trisaccharide compound; the method comprises the following steps: connecting galactose to a non-reducing terminal of a trisaccharide compound through a beta 1, 3-glucosidic bond by using a one-pot multi-enzyme system to generate a tetrasaccharide compound: connecting glucuronic acid to a non-reducing terminal of the tetrasaccharide compound through a beta 1, 3-glucosidic bond by using the one-pot multi-enzyme system to generate a pentasaccharide compound; a one-pot multi-enzyme system is utilized to obtain a sulfuric acid group from PAPS, and the sulfuric acid group is transferred to a C3 site of glucuronic acid at the tail end of a pentasaccharide compound to form an HNK-1 epitope. According to the method disclosed by the invention, the preparation of the HNK-1 can be realized without protection and deprotection strategies. And the prepared I-type HNK-1 antigen has relatively high affinity to an anti-MAG antibody.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Mesothelin (MSLN).

The application discloses a chicken salmonella pullorum strain stably expressing variant O antigen and a construction method and application thereof, and constructs an expression plasmid containing a J23119 promoter and a SPUL_2404 gene, and then the expression plasmid is transferred into chicken salmonella pullorum, so that a chicken salmonella pullorum strain overexpressing the SPUL_2404 gene is constructed to stably express the variant O antigen, and agglutination test shows that the strain only has a typical agglutination reaction with chicken salmonella pullorum variant serums, and does not have a typical agglutination reaction with chicken salmonella pullorum standard serums, and after subculture, O antigens of all subclone colonies are stable, and only have a typical agglutination reaction with the variant serums, so that the strain can be used for preparing chicken salmonella pullorum variant agglutination antigens.

The application provides a new crown vaccine carrier and application thereof. Composed of SARS-CoV-2 RBD as an antigen and STING agonist diABZI coupled with yeast beta-glucan particles. Compared with the diABZI-RBD vaccine alone, the GP-diABZI-RBD vaccine shows sustained vaccine release and elicits a more persistent immune response in mice. Intraperitoneal injection of GP-diABZI-RBD in mice can cause significant cellular and humoral immune responses. Using a replicable virus-like particle system based on pseudovirus particles, we determined that this vaccine can effectively induce effective and persistent neutralizing antibodies against the prototype and VOC, respectively. In particular, the prototype RBD antigen provided by the GP-diABZI-RBD vaccine shows a stronger and longer humoral immune response and antiviral protection.

The application discloses a charge-regulated antigen protein capable of enhancing the synergistic immunization effect with an adjuvant, and the synergistic effect with a charged adjuvant is changed by precisely regulating the surface charge of the antigen protein, so that the vaccine immunization effect is significantly enhanced, and the use dose of the antigen and the adjuvant is greatly reduced. The application also provides a variety of charge-regulated antigen protein variants obtained by using the above method and a synergistic composition of the antigen protein variants and the adjuvant, and application of the antigen protein variants and the synergistic composition in the biological medicine field.

The invention belongs to the technical field of biology, and particularly relates to preparation and application of a swine A type FMDV VP1 antigen and single factor positive serum. The sequence of the expression gene of the swine A type FMDV VP1 antigen is as shown in SEQ ID NO. 1. Through the integral technical scheme of combining sequence-driven conservative site screening, expression and immunological verification, the key problems of antigen mismatch, difficult recombinant protein expression, poor diagnostic reagent universality and the like in the prior art are solved; and the effectiveness and generalizability of the vaccine, the diagnostic reagent and the monitoring means in practical application are obviously enhanced.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.